Both US List And Net Drug Price Increases Have Been Substantial, JAMA Study Finds
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.
You may also be interested in...
Analytics tool plays key role in helping agency oversee quality of 1,800 newly registered hand sanitizer facilities despite travel restrictions.
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.